{"version":"1.0","type":"link","title":"Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.","author_name":"Arriola E 외","author_url":"https://prs-insight.online/author/Arriola%20E","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/94204","thumbnail_width":1200,"thumbnail_height":630}